Q2 2021

Filed Aug 11, 2021 · 10-Q · 42 days after period end · 0001826466-21-000118

Q2 2021 · 10-Q

Revenue—

Net Income

-$2.96K

no prior Q2 2020 on file

EPS Diluted

$0.00

no prior Q2 2020 on file

Operating Income-$2,959—

Operating Cash Flowderived-$2,959—

Same quarter

no prior Q2 2020 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end

Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR